Neurotech Granted Permanent J-Code (J3403) for ENCELTO™ (revakinagene taroretcel-lwey), Effective October 1, 2025

CUMBERLAND, R.I.--(BUSINESS WIRE)--Neurotech Pharmaceuticals, Inc., a private biotech company focused on developing transformative therapies for chronic eye diseases, today announced that the Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-Code (J3403) to ENCELTO™, effective October 1, 2025. ENCELTO is approved in the U.S. to treat adults with idiopathic Macular Telangiectasia Type 2 (MacTel), a retinal disease that causes progressive vision loss. J-codes are perma